BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...

BioMarin是一家成立于1997年的生物技术公司，专注于为基因定义疾病开发治疗方法。该公司宣布PEGASUS试验结果是向可能为年轻PKU患者提供新治疗选择迈出的重要一步。凭借 InvestingPro ...

BioMarin's Phase 3 trial shows Palynziq significantly reduces blood Phe in adolescents with PKU. The company plans a ...

Investing.com — BioMarin Pharmaceutical Inc.股价已达到52周低点，跌至60.63美元，投资者正在应对充满挑战的市场环境。该公司市值为116亿美元，市盈率为27， InvestingPro 分析表明，该股票目前的交易价格低于其公允价值。这家以开发罕见疾病创新疗法而闻名的生物技术公司，其股价在过去一年中出现显著波动，最终较上年同期下跌了30.05%。尽管出现 ...

BioMarin BMRN has announced positive results from the phase III PEGASUS study evaluating Palynziq (pegvaliase) in adolescents aged 12-17 years with phenylketonuria (PKU). The study achieved its ...

BioMarin Pharmaceutical has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its ...

SAN RAFAEL, CA, USA I April 2, 2025 I BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy ...

San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) compared to diet alone in 55 adolescents aged 12-17 with ...

Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a ...

PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...

(Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering in ...